ArticleJournal of the American College of Cardiology2020
Limitations of Contemporary Guidelines for Managing Patients at High Genetic Risk of Coronary Artery Disease.
Article in Journal of the American College of Cardiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07039123 (Polygenic Risk Score to Optimize Primary Prevention in Intermediate Risk Population), which is not on this map. Cited by 82 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Polygenic Risk Score to Optimize Primary Prevention in Intermediate Risk Population (PERSONAL)
Who cites it
82 citing papers in PubMed, 3 syntheses or guidelines pooled it, 137 citations in OpenAlex.
- Polygenic Risk Score and Statin Relative Risk Reduction for Primary Prevention of Myocardial Infarction in a Real-World Population.Clinical pharmacology and therapeutics · 2022 · on this mapPooled it
- A polygenic risk score improves risk stratification of coronary artery disease: a large-scale prospective Chinese cohort study.European heart journal · 2022Pooled it
- Transethnic Transferability of a Genome-Wide Polygenic Score for Coronary Artery Disease.Circulation. Genomic and precision medicine · 2021Pooled it
- Prognostic Value of a Polygenic Risk Score for Coronary Heart Disease in Individuals Aged 70 Years and Older.Circulation. Genomic and precision medicine · 2022Trial
- Development and Validation of a Clinical Polygenic Risk Report in U.S.-Based Health Systems for 8 Cardiovascular Conditions.Journal of the American College of Cardiology · 2026Article
- Inherited risk of coronary artery disease: redefining care with imaging and genetics.Nature reviews. Cardiology · 2026Review
- Improving Polygenic Risk Prediction for Atherosclerotic Cardiovascular Disease in East Asian Populations.JACC. Asia · 2026Review
- Capturing multi-disease states on a spectrum with machine learning and routine clinical data.Med (New York, N.Y.) · 2026Article
- Polygenic risk score refines cardiovascular disease risk in individuals with type 2 diabetes at borderline or intermediate risk.Journal of diabetes investigation · 2026Article
- Article
- Analytic Choices Shape Genomic Risk Estimates from Electronic Health Records: Coronary Heart Disease in eMERGE IV.medRxiv : the preprint server for health sciences · 2026Article
- Polygenic risk scores enhance LDL cholesterol-based risk stratification for coronary artery disease.American journal of preventive cardiology · 2026Article
- Addition of CAD polygenic risk score to coronary artery calcium score enhances prediction of MACE.Frontiers in cardiovascular medicine · 2026Article
- Genetic and Conventional Risk Stratification Are Complementary for Primary Prevention of CAD.Methodist DeBakey cardiovascular journal · 2026Review
- Genetics and context for precision health in Greater Boston.Nature communications · 2025Article
- Importance of Clinical, Laboratory, and Genetic Risk Factors for Incident CAD.Circulation. Genomic and precision medicine · 2025Article
- Meta-prediction of coronary artery disease risk.Nature medicine · 2025Article
- Polygenic risk scores improve CAD risk prediction in individuals at borderline and intermediate clinical risk.NPJ cardiovascular health · 2025Article
- Risk in Repose: Sedentary Behavior and Genetic Susceptibility to Cardiovascular Disease.Journal of the American Heart Association · 2025Article
- Precision Medicine in Cardiovascular Disease Prevention: Clinical Validation of Multi-Ancestry Polygenic Risk Scores in a U.S. Cohort.Nutrients · 2025Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
28 authors at 10 institutions in 1 country.
Funding
Abstract
backgroundPolygenic risk scores (PRS) for coronary artery disease (CAD) identify high-risk individuals more likely to benefit from primary prevention statin therapy. Whether polygenic CAD risk is captured by conventional paradigms for assessing clinical cardiovascular risk remains unclear.
objectivesThis study sought to intersect polygenic risk with guideline-based recommendations and management patterns for CAD primary prevention.
methodsA genome-wide CAD PRS was applied to 47,108 individuals across 3 U.S. health care systems. The authors then assessed whether primary prevention patients at high polygenic risk might be distinguished on the basis of greater guideline-recommended statin eligibility and higher rates of statin therapy.
resultsOf 47,108 study participants, the mean age was 60 years, and 11,020 (23.4%) had CAD. The CAD PRS strongly associated with prevalent CAD (odds ratio: 1.4 per SD increase in PRS; p < 0.0001). High polygenic risk (top 20% of PRS) conferred 1.9-fold odds of developing CAD (p < 0.0001). However, among primary prevention patients (n = 33,251), high polygenic risk did not correspond with increased recommendations for statin therapy per the American College of Cardiology/American Heart Association (46.2% for those with high PRS vs. 46.8% for all others, p = 0.54) or U.S. Preventive Services Task Force (43.7% vs. 43.7%, p = 0.99) or higher rates of statin prescriptions (25.0% vs. 23.8%, p = 0.04). An additional 4.1% of primary prevention patients may be recommended for statin therapy if high CAD PRS were considered a guideline-based risk-enhancing factor.
conclusionsCurrent paradigms for primary cardiovascular prevention incompletely capture a polygenic susceptibility to CAD. An opportunity may exist to improve CAD prevention efforts by integrating both genetic and clinical risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.